戻る
「早戻しボタン」を押すと検索画面に戻ります。 [閉じる]

コーパス検索結果 (１語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します
1 -8.2 months (74% had a documented history of atrial tachyarrhythmias).
2 lantable cardiac monitoring device to detect atrial tachyarrhythmia.
3 iated with a higher risk of sudden death and atrial tachyarrhythmia.
4  and may serve as a source of the adrenergic atrial tachyarrhythmia.
5 e, left ventricular systolic dysfunction, or atrial tachyarrhythmia.
6 ovel noncontact mapping system for assessing atrial tachyarrhythmias.
7 ved an implantable cardiac monitor to detect atrial tachyarrhythmias.
8 intake was not allowed except for documented atrial tachyarrhythmias.
9 bile device to record a daily ECG and detect atrial tachyarrhythmias.
10 (LAAI) may occur during catheter ablation of atrial tachyarrhythmias.
11 tion into epicardial fat pads for preventing atrial tachyarrhythmias.
12  p = 0.04) and had a comparable incidence of atrial tachyarrhythmias.
13 ory of IAT or by the development of in-trial atrial tachyarrhythmias.
14 technique for managing children with JET and atrial tachyarrhythmias.
15 on occurred in 7 animals, simulating a rapid atrial tachyarrhythmias.
16 d points were recurrence of AF and organized atrial tachyarrhythmias.
17 ears between patients with and those without atrial tachyarrhythmias.
18 ECNA) is an invariable trigger of paroxysmal atrial tachyarrhythmias.
19 morbidity and mortality rates from recurrent atrial tachyarrhythmias.
20 hom 19 had a history of documented sustained atrial tachyarrhythmias.
21 herapies to reduce the burden of spontaneous atrial tachyarrhythmias.
22 erapies for prevention and/or termination of atrial tachyarrhythmias.
23                          Eleven patients had atrial tachyarrhythmias: 10 of 11 had immediate success,
24       Reasons included the development of an atrial tachyarrhythmia (18%), loss of left ventricular c
25 ower heart rates were more likely to develop atrial tachyarrhythmias, a dual-chamber rate-modulated p
26 ed recurrence of symptomatic or asymptomatic atrial tachyarrhythmia (AF, atrial flutter, or atrial ta
27 ers the risk of atrial fibrillation or other atrial tachyarrhythmias (AF/AT), or if postimplantation
28 te of initial procedural failure, documented atrial tachyarrhythmia after a 3-month blanking period,
29 te of initial procedural failure, documented atrial tachyarrhythmia after a 3-month blanking period,
30          Success was defined as freedom from atrial tachyarrhythmia after a 3-month blanking period.
31 during 12.9+/-9.4 months, and any documented atrial tachyarrhythmia after the 3-month blanking period
32 riate therapy due to atrial fibrillation and atrial tachyarrhythmias, also evaluated as ATP or shock
33  and initial treatment of AF, coexistence of atrial tachyarrhythmia and (2) progression of paroxysmal
34 n the 52 of 269 patients who had episodes of atrial tachyarrhythmia and had >/=30 days of follow-up w
35     The outcomes measured were recurrence of atrial tachyarrhythmia and the incidence of adverse even
36 ontrolled trial of 2,718 patients evaluating atrial tachyarrhythmias and anticoagulation for patients
37  new molecular and mechanistic insights into atrial tachyarrhythmias and identifies Kir3.x as a promi
38 outcomes included symptomatic recurrences of atrial tachyarrhythmias and quality of life measures ass
39                   Early recurrences (ERs) of atrial tachyarrhythmia are common after catheter ablatio
40                                              Atrial tachyarrhythmias are a complication of Fontan sur
41 ct to the incidence of a first recurrence of atrial tachyarrhythmia, as assessed by continuous rhythm
42 ablation to PVI did not enhance freedom from atrial tachyarrhythmia at 12 months, and it led to incre
43  drugs resulted in a lower rate of recurrent atrial tachyarrhythmias at 2 years.
44 f cardiac resynchronization therapy (CRT) on atrial tachyarrhythmia (AT) susceptibility in patients w
45    Secondary endpoints included freedom from atrial tachyarrhythmias (AT) at 6 and 12 months, peripro
46 e into a subsequent reduction in the risk of atrial tachyarrhythmias (AT).
47  included ventricular tachyarrhythmia (VTA), atrial tachyarrhythmia (ATA), ICD therapies, VTA burden
48                                     However, atrial tachyarrhythmias (ATA) are a common early complic
49 nts, 37 of whom also demonstrated persistent atrial tachyarrhythmias (ATAs).
50 t was the first documented recurrence of any atrial tachyarrhythmia (atrial fibrillation, atrial flut
51 upporting an association between subclinical atrial tachyarrhythmias (ATs) detected by cardiac implan
52 rocardiogram (PSAECG) for risk assessment of atrial tachyarrhythmias (ATs) in patients after Fontan o
53 ventricular tachyarrhythmias have documented atrial tachyarrhythmias before implantation.
54 ficacy end point was defined as freedom from atrial tachyarrhythmia between 90 and 365 days after a s
55 ary end point was the first recurrence of an atrial tachyarrhythmia between day 91 and day 365 after
56       The primary end point was freedom from atrial tachyarrhythmias between 91 and 365 days after in
57 erence was observed in 12-month freedom from atrial tachyarrhythmias between an index ablative approa
58  atrial therapies resulted in a reduction of atrial tachyarrhythmia burden from a mean of 58.5 to 7.8
59 hyarrhythmias had a significant reduction in atrial tachyarrhythmia burden with use of atrial pacing
60  the effectiveness and safety of terminating atrial tachyarrhythmias clinically.
61 athogenic mutation in a familial syndrome of atrial tachyarrhythmia, conduction system disease (CSD),
62            One-year freedom from symptomatic atrial tachyarrhythmia defined by continuous rhythm moni
63                        One-year freedom from atrial tachyarrhythmia defined by continuous rhythm moni
64 ng cardioversion for termination), recurrent atrial tachyarrhythmia (defined as atrial fibrillation,
65 rimary outcome event, 11 had had subclinical atrial tachyarrhythmias detected by 3 months, and none h
66                     By 3 months, subclinical atrial tachyarrhythmias detected by implanted devices ha
67           This study sought to determine the atrial tachyarrhythmia duration and burden associated wi
68 ients with and those without device-detected atrial tachyarrhythmias during the first year.
69               The time and duration of every atrial tachyarrhythmia episode recorded on implantable c
70  patients for 3 months to detect subclinical atrial tachyarrhythmias (episodes of atrial rate >190 be
71  vein isolation (PVI) as early recurrence of atrial tachyarrhythmia (ERAT) may be due to transient pr
72 adverse events were strongly associated with atrial tachyarrhythmia, extracardiac arteriopathy, and a
73 ablation resulted in better 2-year organized atrial tachyarrhythmia-free survival (71% [62%-79%] vers
74                                    Organized atrial tachyarrhythmia-free survival was similar after S
75 as (junctional ectopic tachycardia [JET] and atrial tachyarrhythmias) frequently complicate recovery
76                                Patients with atrial tachyarrhythmia >/=30 s within the 3-month blanki
77                   At 1 year, a recurrence of atrial tachyarrhythmia had occurred in 66 of 154 patient
78                                  Symptomatic atrial tachyarrhythmia had recurred in 11.0% of the pati
79  patients with a standard ICD indication and atrial tachyarrhythmias had a significant reduction in a
80 nts who had the Fontan procedure, those with atrial tachyarrhythmias had longer P-wave duration (159+
81                                Patients with atrial tachyarrhythmias had longer paced (153+/-29 versu
82 xis decreases the incidence of postoperative atrial tachyarrhythmias have had mixed results and were
83 including age at the first visit, history of atrial tachyarrhythmia, heart failure, New York Heart As
84 e the effect of both history of intermittent atrial tachyarrhythmias (IAT) and in-trial IAT on the ri
85 at included 12-month freedom from documented atrial tachyarrhythmia (ie, atrial fibrillation, atrial
86 ciation with a higher incidence of sustained atrial tachyarrhythmia, implying that sinus node dysfunc
87                      There was recurrence of atrial tachyarrhythmia in 222 of 785 (28%) patients who
88 1.7% of patients experienced a recurrence of atrial tachyarrhythmia in the first year of follow-up.
89  can suppress sympathetic outflow and reduce atrial tachyarrhythmias in ambulatory dogs.
90 ies and reduces the incidences of paroxysmal atrial tachyarrhythmias in ambulatory dogs.
91 entricular rate during postoperative JET and atrial tachyarrhythmias in our young canine open heart s
92 iods, was associated with the development of atrial tachyarrhythmias in pacemaker patients.
93 icacy of novel pacing therapies for treating atrial tachyarrhythmias in patients receiving a dual-cha
94  become the treatment strategy of choice for atrial tachyarrhythmias in patients with congenital hear
95 based atrial pacing for treating spontaneous atrial tachyarrhythmias in patients with implantable car
96 the implantation of an ICD and 2 episodes of atrial tachyarrhythmias in the preceding year received a
97 perform high-resolution multisite mapping of atrial tachyarrhythmias in vivo.
98 anges of atrial electrophysiology and induce atrial tachyarrhythmias, including atrial tachycardia an
99                                              Atrial tachyarrhythmias inducible with programmed electr
100                                              Atrial tachyarrhythmia is a common cause of morbidity an
101              The mechanism of the adrenergic atrial tachyarrhythmia is unclear.
102  has been implicated in the genesis of focal atrial tachyarrhythmias, its gross anatomic and microsco
103            In 8 of 9 patients with >1 event, atrial tachyarrhythmia, itself a known risk factor for m
104     The primary end point was any documented atrial tachyarrhythmia lasting >30 seconds beyond 3 mont
105 rrence endpoint was any post-90-day blanking atrial tachyarrhythmias lasting 30 s or longer.
106                                Patients with atrial tachyarrhythmias late after Fontan operation have
107                        In patients with CHD, atrial tachyarrhythmias may result from IART or IDAF.
108                        A first recurrence of atrial tachyarrhythmia occurred in 56.5% of patients wit
109                                    Recurrent atrial tachyarrhythmia occurred in 87 patients in the ab
110             The time to the first documented atrial tachyarrhythmia of more than 30 seconds (symptoma
111 end point was freedom from recurrence of any atrial tachyarrhythmia, outside a 90-day blanking period
112  persistent atrial fibrillation or recurrent atrial tachyarrhythmia over 3 years of follow-up than in
113                                              Atrial tachyarrhythmias, particularly atrial fibrillatio
114 abnormality on the ECG and a diagnosis of an atrial tachyarrhythmia predict sudden death.
115        All patients had medically refractory atrial tachyarrhythmias, primarily atrial fibrillation (
116 a outcomes (freedom from any, or symptomatic atrial tachyarrhythmia), produce clinically meaningful i
117                                              Atrial tachyarrhythmias recurred in 28 PVI-only group pa
118                                              Atrial tachyarrhythmia recurrence >=30 s remains the pri
119 success and postblanking 1-year freedom from atrial tachyarrhythmia recurrence (>30 seconds), redo ab
120                                              Atrial tachyarrhythmia recurrence after rhythm control i
121 the relationship between the timing of first atrial tachyarrhythmia recurrence and subsequent AF burd
122 n ostial PVI in achieving freedom from total atrial tachyarrhythmia recurrence at long-term follow-up
123      The primary end point, freedom from any atrial tachyarrhythmia recurrence between 91 and 365 day
124            The observed rate of postablation atrial tachyarrhythmia recurrence is highly dependent on
125                                              Atrial tachyarrhythmia recurrence remains the primary en
126         Overall, the primary end point of no atrial tachyarrhythmia recurrence was met in 79% (cryoba
127                                          The atrial tachyarrhythmia recurrence was observed in 10 pat
128 t-term follow-up, 17/191 patients (9%) had a atrial tachyarrhythmia recurrence.
129 , 61%) or persistent atrial fibrillation and atrial tachyarrhythmia recurrences despite previous succ
130 ion, we found a significantly higher risk of atrial tachyarrhythmia recurrences in patients with ECs
131            MIL ablation may reduce organized atrial tachyarrhythmia recurrences.
132 ], 1.24 to 8.78) and a clinical diagnosis of atrial tachyarrhythmia (relative risk, 5.18; 95% CI, 2.2
133                                  Subclinical atrial tachyarrhythmias remained predictive of the prima
134 toms, but the rates of exercise intolerance, atrial tachyarrhythmias, right ventricular dysfunction,
135 defibrillators with recurrent ventricular or atrial tachyarrhythmias should not interfere with proper
136                         The median burden of atrial tachyarrhythmia showed no significant difference
137 ary artery bypass graft provided substantial atrial tachyarrhythmia suppression both early as well as
138  systems can automatically detect and record atrial tachyarrhythmias that may be asymptomatic.
139 hundred and forty-four patients with CHD and atrial tachyarrhythmias undergoing radiofrequency cathet
140  were "CPAP nonusers." The recurrence of any atrial tachyarrhythmia, use of antiarrhythmic drugs, and
141            One-year freedom from symptomatic atrial tachyarrhythmia was 77.2% in patients without ER
142                                Recurrence of atrial tachyarrhythmia was comparable in both groups (20
143                              A recurrence of atrial tachyarrhythmia was observed between day 91 and d
144 d on the month where the first recurrence of atrial tachyarrhythmia was observed, after a 2-month bla
145                                  The induced atrial tachyarrhythmia was suppressed in nine patients (
146 ystemic embolism associated with subclinical atrial tachyarrhythmias was 13%.
147 Kaplan-Meier point estimate for freedom from atrial tachyarrhythmias was 51.7% (CI, 40.9%-65.4%) for
148  recurrences of atrial fibrillation or other atrial tachyarrhythmias was evaluated at the end of the
149                                  Subclinical atrial tachyarrhythmias were associated with an increase
150                    Second, the patients with atrial tachyarrhythmias who had the Fontan procedure had
151 3 +/- 12 ms) in patients with suppression of atrial tachyarrhythmia with dual-site atrial pacing comp
152                                  Subclinical atrial tachyarrhythmias, without clinical atrial fibrill

 
Page Top